Comparator supply for NCT04589845
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Sponsor: Hoffmann-La Roche (INDUSTRY). Phase: PHASE2. Status: Active Not Recruiting. Countries: United States, Australia, Belgium, Brazil, Canada, China, Denmark, France, Germany, Hong Kong, Israel, Italy, Japan, New Zealand, Poland, Portugal, Puerto Rico, Singapore, South Korea, Spain, Switzerland, Taiwan, United Kingdom. Last update posted 2026-09-04.
Registry record: https://clinicaltrials.gov/study/NCT04589845.
Canadian-labelled alectinib
1 marketed Canadian product(s) from 1 manufacturer(s) contain alectinib (alectinib hydrochloride). Available strengths: 150 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled atezolizumab
3 marketed Canadian product(s) from 1 manufacturer(s) contain atezolizumab. Available strengths: 1200 MG / 20 ML, 125 MG, 840 MG / 14 ML. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled entrectinib
2 marketed Canadian product(s) from 1 manufacturer(s) contain entrectinib. Available strengths: 100 MG, 200 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled inavolisib
2 marketed Canadian product(s) from 1 manufacturer(s) contain inavolisib. Available strengths: 3 MG, 9 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled trastuzumab emtansine
2 marketed Canadian product(s) from 1 manufacturer(s) contain trastuzumab emtansine. Available strengths: 100 MG, 160 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
What we supply
- Canadian-labelled comparator sourced through licensed Canadian supply
- Certificate of Analysis for every batch
- Batch number and expiry documentation, with retained records
- Blinding-ready packaging and over-encapsulation on request
- 2–8 °C validated cold chain with temperature logging where required
- Health Canada Drug Establishment Licence #3-002896
Frequently asked questions
Can Nexara supply Canadian-labelled alectinib as a trial comparator?
Yes. We source Canadian-marketed alectinib under Health Canada Drug Establishment Licence #3-002896 and ship it with Certificate of Analysis, batch number and expiry documentation for use as a comparator or rescue supply in NCT04589845.
What documentation comes with each shipment?
Certificate of Analysis, manufacturer batch and expiry records, chain-of-custody documentation from the Canadian supply chain, and temperature records where cold chain applies. Blinding-ready packaging is available on request.
How long does comparator supply take?
Quotes are returned within one business day. Lead time depends on the presentation and the destination country's import route — typically 10 to 21 days once the importer's licence and any notification are in place.
Request comparator quote
Request comparator quote or call +1-431-588-9055.